ailanthone has been researched along with mdv 3100 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, A; Chen, H; Cong, X; Gao, S; He, Y; Hu, M; Liu, M; Peng, S; Qin, M; Wang, J; Wang, L; Wang, X; Wu, H; Yi, Z | 1 |
| Liu, M; Peng, S; Yi, Z | 1 |
2 other study(ies) available for ailanthone and mdv 3100
| Article | Year |
|---|---|
Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer.
Topics: Alternative Splicing; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Molecular Chaperones; Molecular Targeted Therapy; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Phosphoproteins; Prostaglandin-E Synthases; Prostatic Neoplasms, Castration-Resistant; Protein Stability; Proteolysis; Quassins; Receptors, Androgen; Xenograft Model Antitumor Assays | 2016 |
Ailanthone: a new potential drug for castration-resistant prostate cancer.
Topics: Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quassins | 2017 |